Envoy Medical Inc., a hearing health company specializing in fully implanted hearing devices, announced that its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant is progressing as planned. All 10 participants in the first stage of the trial have successfully completed their one-month follow-up visits, with investigational sites reporting that the visits are proceeding as expected. The participants are able to hear without externally worn devices, and no serious adverse events have been reported. Envoy Medical is encouraged by the positive momentum and is considering accelerating plans for expansion and commercialization of the device. Further updates on the trial will be provided to the shareholder community.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。